Compare Caterpillar Inc (CAT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Caterpillar Inc vs BIO-TECHNE Corp — how do they compare? Caterpillar Inc trades at $848.95 (market cap $385.01B), while BIO-TECHNE Corp trades at $72.07 (market cap $11.24B). The key difference: Caterpillar Inc is far larger — about 34.3× BIO-TECHNE Corp's market cap, and Caterpillar Inc pays the higher dividend (0.78%). Which is the better fit depends on your goals.
| CAT | TECH | |
|---|---|---|
Market Cap | $385.01B | $11.24B |
Sector | Industrials | Health |
52-Week High | $1.06K | $72.29 |
52-Week Low | $407.79 | $43.31 |
Enterprise Value | $423.45B | $11.32B |
Dividend Yield | 0.78% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Caterpillar (CAT) trades at $842.19, down 1.72% on the day, with a bearish technical signal but strong fundamentals including a 56.99% ROE and consistent earnings beats. Revenue reached $67.59B in 2025, with net income of $8.88B, though margins dipped from 2024. Analysts maintain a buy consensus with a $1,010 price target, citing AI-driven demand from data centers as a growth catalyst, while technical indicators show resistance near $862 and support at $829.
Outlook is mixed: robust profitability and dividend growth support upside, but elevated P/E of 36.27 and bearish technicals pose near-term risks. Investors should weigh strong institutional sentiment against potential volatility from macroeconomic pressures and valuation concerns.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Caterpillar Inc
Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.
Read more on CAT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
